Cell-El, The ASD Bio-marker Company

Cell-El’s breakthrough research of diagnostic bio-markers should lead to more objective and earlier diagnosis of ASD.   This is paving the way for earlier intervention, better outcomes and the testing of promising  new therapies including stem cells and modulation of the microbiome.


Your child’s participation in Cell-El’s successful clinical diagnostic study of young children is paving the way to targeted effective therapy and the possibility of earlier intervention.


Cell-El delves beyond the behavioral observation of ASD to its underlying biological mechanisms. Our diagnostic findings provide the rationale for targeted treatments.


Parents and clinicians join the Cell-El team in its multi-national clinical collaborations which have approvals from the Helsinki ethics committees and the Israeli Ministry of Health.

  1. Dr. Gesundheit brings his scientific and clinical experience from The Hospital for Sick Children, Toronto, Canada, the department of Pediatric Hematology-Oncology at Soroka Hospital Beer Sheva, Israel and Hadassah Hospital, Jerusalem Israel to his methodical research in ASD and its immunological aspects as well as to the rationale for the treatment with stem cells.
Beni Gesundheit


Founder &  Chief Medical Officer (CMO)

Dr. Samuels has over 36 years of senior management experience in startup, mid size and large companies in the in vitro diagnostic (IVD) industry including Orgenics, Alere and Abbott. He has led the development, manufacturing and CE and FDA approval of many in vitro diagnostics (IVD) products.

Fred Samuels

Fred Samuels, PhD

Chief Executive Officer (CEO)

Dr. Ellis has 35 years of senior management experience for R&D companies – large, medium, small, startup and incubators. His development and project leadership skills have brought therapeutics to the clinic and to market.

Ronald Ellis

Ronald Ellis, PhD MBA

Chief Scientific Officer (CSO)

Mr. Labinsky has extensive experience and planning in working with companies in business, corporate and investment management. Baruch is licensed by the Israel Securities Authority as an investment portfolio manager.

Baruch Labinsky

Baruch Labinsky, MA

Chief Financial Officer (CFO)

A strategic thinker and contingency planner, Dr Piwko has the analytical skills for integrating and interpreting interdisciplinary projects. He has 20 years of experience conducting health economic research for the pharma, biotech, and medical devices industry. 

Charles Piwko

Charles Piwko, PhD

Director of Business Development

Mrs. Hochbaum has over 20 years of experience working with families of children with ASD. She speaks with parents and clinicians about our ASD diagnostic study, thereby enabling our research. Speak with Leah if you want to join our team and work together at solving the autism challenge! 

Leah Hochbaum


Recruitment Coordinator

Dr. Zisman has over ten years of experience in the fields of biotechnology, biochemistry, cell biology, immunology, and bioassays. He is responsible for laboratory issues, assay development and immunology.

Philip Zisman

Philip David Zisman, PhD

Immunologist and Laboratory Director

Dr. Posen consults at Cell-El, and prepares clinical trial-related documents and manuscripts for publication. She brings over ten years of experience as a medical and scientific writer, supporting both academic researchers and pharmaceutical and medical device R&D teams. 

Yehudit Posner

Yehudit Posen, PhD

Medical Researcher and Scientific Writer

Dr. Refoel Guggenheim is a clinical pediatrician affiliated at the Triemli Hospital Zurich, Switzerland. He focuses on pediatric developmental medicine and Allergy/Clinical Immunology. He is engaged in Medical Ethics and organizes Conferences on Jewish Medical Ethics. He is co-editor of the pediatric journal Kinderärzte Schweiz.

Dr Guggenheim

Refoel Guggenheim, MD

Study-Coordinator, Switzerland and Europe.

Ms. Ansel’s Master’s thesis research of Immunogenetics with a focus on genetic variation in non-human primates as well as her work in genetics, immunology and neuroscience labs in the USA and Israel, have been a big asset to her work at Cell-El.

Ashley Ansel

Ashley Ansel, MA


Mrs. Suna has over 20 years of web design and development experience with small to large organizations as well as pharmaceutical companies. Susan works closely with the team crafting the website and its messaging.

Susan Suna

Susan Suna, MA

Web Development

Parents Ask

Cell-El’s research shows an important association between the immune system and ASD. These findings are the basis for targeted treatments.  For more information please read our Diagnostics page.

The entire procedure takes less than an hour.  It involves:

  • Signing a consent form
  • Filling out a medical questionnaire with a team member
  • Drawing up to 5 ml venous blood
  • The child does not have to fast

The diagnostic test involves drawing about 5 ml of venous blood and this standard procedure has minimal risk. 

We look forward to your participation in the Cell-El diagnostic study. Please read the information below regarding the inclusion and exclusion criteria for the following cohorts: 1. Infants and their mothers and 2. Children pre and post Stem Cell Therapy (SCT). Then please fill out the appropriate form.

  • Cohort of infants and their mothers: Mothers of high-risk infants and infants aged 10-18 months not diagnosed with ASD but with a sibling diagnosed with ASD according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV (299.00) or DSM-V (299.00) ± ADOS (herein termed “high-risk infants”) or
  • Cohort of children pre and post SCT: Male and female children age 2-12 years Diagnosed autism spectrum disorder (ASD) according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV (299.00) or DSM-V (299.00) undergoing stem cell therapy.
  • For both cohorts: Informed consent signed by the parents
  • For both cohorts: Child and/or mother that have been treated with systemic steroids or have undergone immune suppression treatment within the last 6 months
  • Child and/or mother diagnosed with severe infectious diseases or sepsis over the last 6 months
  • Child and/or mother with hematological or malignant disorder
  • For children in the SCT cohort: No new planned treatment (other than SCT) for at least 6 months from planned stem cell transplantation date and no new treatments (other than SCT) started within 6 months before planned transplantation date.
  • Child with ASD treated for a severe convulsive disorder

If you are a parent or a clinician of a child diagnosed with ASD, please click here to fill out the appropriate form.